We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Acute Effects of Cafestol on Glucose Metabolism in Subjects With Type-2-diabetes.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04908904
Recruitment Status : Completed
First Posted : June 1, 2021
Last Update Posted : February 28, 2022
Sponsor:
Collaborator:
Aarhus University Hospital
Information provided by (Responsible Party):
University of Aarhus

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Acute, double-blinded, randomized, cross-over cafestol intervention study with sixteen participants with T2D participating in two OGTTs.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 2 Dietary Supplement: Cafestol Dietary Supplement: Placebo Not Applicable

Detailed Description:
The study is an acute, double-blinded, randomized, cross-over intervention study with sixteen participants with T2D. Initially, a blood sample is obtained (t=-15 min) and at time point 0, the participants will ingest a tablet containing either 12 mg cafestol or placebo. Immediately hereafter an OGTT commences with ingestion of a 75 g glucose solution. In the following 3 hours blood samples are collected at time points 0, 15, 30, 60, 90, 120 and 180 min. The samples will be used for determination of plasma glucose, insulin and cafestol, as well as GLP-1 and GIP. After a one-week washout period, the subject will undergo the same set-up again, however now with the opposite intervention / placebo.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Acute Effects of Cafestol on Glucose Metabolism in Subjects With Type-2-diabetes.
Actual Study Start Date : May 27, 2021
Actual Primary Completion Date : February 16, 2022
Actual Study Completion Date : February 16, 2022

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Cafestol
12 mg cafestol
 Dietary Supplement: Cafestol
Capsule with 12 mg cafestol
Placebo Comparator: Placebo
Placebo
 Dietary Supplement: Placebo
Placebo capsule without cafestol


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Area under the curve for glucose [ Time Frame: -15 to 180 minutes from ingestion of intervention/placebo capsule and 75 g. glucose solution ]
    Area under the curve for glucose during OGTT after ingestion of cafestol or placebo capsule


Secondary Outcome Measures :
  1. Area under the curve for insulin-response [ Time Frame: -15 to 180 minutes from ingestion of intervention/placebo capsule and 75 g. glucose solution ]
    Area under the curve for insulin response during OGTT after ingestion of cafestol or placebo capsule

  2. Area under the curve for cafestol [ Time Frame: -15 to 180 minutes from ingestion of intervention/placebo capsule and 75 g. glucose solution ]
    Area under the curve for cafestol during OGTT after ingestion of cafestol or placebo capsule

  3. Area under the curve for GLP-1 [ Time Frame: -15 to 180 minutes from ingestion of intervention/placebo capsule and 75 g. glucose solution ]
    Area under the curve for GLP-1 (glucagon-like peptide-1) during OGTT after ingestion of cafestol or placebo capsule

  4. Area under the curve for GIP [ Time Frame: -15 to 180 minutes from ingestion of intervention/placebo capsule and 75 g. glucose solution ]
    Area under the curve for GIP (Glucose-dependent insulinotropic polypeptide) during OGTT after ingestion of cafestol or placebo capsule


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Type 2 Diabetes defined by standard Danish guidelines
  • HbA1c ≥48 mmol/mol unless successfully treated with antidiabetic drugs and/or diet/exercise intervention

Exclusion Criteria:

  • In treatment with insulin
  • Pregnancy
  • Planned pregnancy
  • Breastfeeding
  • Significant comorbidity expected to unable the subject from completing visits
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04908904


Locations
Layout table for location information
Denmark
Steno Diabetes Center Aarhus
Aarhus, Aarhus N, Denmark, 8200
Sponsors and Collaborators
University of Aarhus
Aarhus University Hospital
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: University of Aarhus
ClinicalTrials.gov Identifier: NCT04908904    
Other Study ID Numbers: cafestol.acute.t2d
First Posted: June 1, 2021    Key Record Dates
Last Update Posted: February 28, 2022
Last Verified: May 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of Aarhus:
Diabetes Mellitus, Type 2
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases